ClearB Therapeutics to Present Pre-Clinical Chronic Hepatitis B Data at EASL 2024
ClearB Therapeutics, Inc., based in Concord, Massachusetts, has announced exciting developments for its therapeutic vaccine candidate, CLB-3000, aimed at achieving a functional cure for Hepatitis B. At the upcoming European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2024 in Milan, two key research abstracts from ClearB will be presented as posters. One of these posters has been specially highlighted as a TOP presentation.
The company’s CEO, Dr. Aileen Rubio, expressed enthusiasm about sharing their preclinical findings with the Hepatitis B research community. Dr. Rubio emphasized the ongoing global health challenge posed by chronic Hepatitis B (CHB) and the urgent need for effective antiviral and immunomodulatory therapies. She highlighted the potential of ClearB’s therapeutic vaccine and other innovative approaches to be integral components of combination treatment strategies.
Specific details of the presentations are as follows:
1. Abstract Number: SAT-339
- Title: Sequential administration of siRNA with an mRNA encoding clearance pro variants of HBsAg exhibits significant antiviral activity in an AAV/HBV mouse model
- Date: Saturday, 8 June 2024
- Time: 9:00 AM GMT+1
- Presenter: Dr. Aditi Deshpande, ClearB Therapeutics
2. Abstract Number: TOP-353
- Title: An mRNA vaccine exhibits anti-viral activity in a mouse model of persistent Hepatitis B infection
- Date: Saturday, 8 June 2024
- Time: 9:00 AM GMT+1
- Presenter: Dr. Aditi Deshpande, ClearB Therapeutics
The EASL International Liver Congress 2024 will serve as a platform for ClearB Therapeutics to showcase its pioneering work on Hepatitis B. The company, co-founded in 2017 by Morningside Ventures with collaboration from Professor Stephen Locarnini and the Victoria Infectious Diseases Reference Laboratory in Melbourne, Australia, focuses on therapeutic vaccines for Hepatitis B. Their research is grounded in proprietary insights from studying rare cases of infection resolution in chronic Hepatitis B patients.
Morningside Ventures, established by the Chan family in 1986, is a key partner in this venture. Known for their dedication to early-stage investments in biopharmaceutical products, Morningside Ventures collaborates with academic pioneers and entrepreneurs to create companies that aim to significantly enhance medical treatment and patient outcomes. Their mission is to invest in promising biomedical research, supporting the translation of scientific advancements into clinical development with the goal of making a meaningful impact on human disease prevention and treatment. The firm’s approach centers on commercial success achieved through real contributions to health care.
ClearB Therapeutics leverages cutting-edge research and collaboration to address the substantial global burden of chronic Hepatitis B. Their innovative therapeutic vaccine, CLB-3000, represents a significant step forward in the quest for effective treatments and potential cures for this pervasive disease. Through their presentations at the EASL International Liver Congress, the company aims to foster greater understanding and collaboration within the Hepatitis B research community, driving forward the development of new therapeutic strategies.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
